SHL Group, QuiO partner to forge next generation of self-treatment

SHL Group and New York-based startup QuiO have announced a strategic partnership on digital technologies that will take the drug delivery industry into connected therapeutics.

SHL is a pioneer in advanced drug delivery systems based on human-centered design and functionality. It has a diverse portfolio of connected products and concepts that meet different patient and customer requirements.

QuiO, winner of the 2017 Accenture Global HealthTech Innovation Challenge, is at the vanguard of digital technologies that allow injectable therapies to reach their full potential. QuiO technologies include the ConnectedRx, a first-of-its-kind cloud-based solution for patient support.

SHL and QuiO believe that connectivity is the key to taking user experience to the next level. The idea of the device as not only a drug carrier, but as a data collector, opens up unique opportunities to support patient adherence and monitor treatment outcomes.

“SHL has pushed to stay at the leading edge of advanced drug delivery for more than 20 years. As the healthcare industry embraces digital and people increasingly take their treatment into their own hands, our natural next step is connectivity that seamlessly captures high-quality data to form a detailed picture of the patient to improve clinical decision-making,” SHL Group founder and CEO Roger Samuelsson said.

QuiO CEO Alexander Dahmani said: "QuiO is excited to contribute hardware technology and provide the full software-stack for SHL's connected devices. Our ConnectedRx solution captures data directly from medical devices, structures and stores it in a secure cloud environment, and serves it to a suite of powerful applications that enable patients, clinicians, and customers to benefit from the data.”

For SHL, partnering with QuiO is an important milestone that will provide entrepreneurial spirit and excellent capabilities to support its ambitions to lead the digital healthcare industry.